Suppr超能文献

生物分析测定中的监管观察

Regulatory observations in bioanalytical determinations.

作者信息

Viswanathan C T

机构信息

US FDA, Division of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, Rockville, MD 20857, USA.

出版信息

Bioanalysis. 2010 Jul;2(7):1325-9. doi: 10.4155/bio.10.85.

Abstract

The concept of measuring analytes in biological media is a long-established area of the quantitative sciences that is employed in many sectors. While academic research and R&D units of private firms have been in the forefront of developing complex methodologies, it is the regulatory environment that has brought the focus and rigor to the quality control of the quantitative determination of drug concentration in biological samples. In this article, the author examines the regulatory findings discovered during the course of several years of auditing bioanalytical work. The outcomes of these findings underscore the importance of quality method validation to ensure the reliability of the data generated. The failure to ensure the reliability of these data can lead to potential risks in the health management of millions of people in the USA.

摘要

在生物介质中测量分析物的概念是定量科学中一个历史悠久的领域,在许多行业都有应用。虽然学术研究机构和私营公司的研发部门一直处于开发复杂方法的前沿,但正是监管环境为生物样品中药物浓度定量测定的质量控制带来了重点和严格要求。在本文中,作者审视了在数年生物分析工作审计过程中发现的监管问题。这些问题的结果强调了高质量方法验证对于确保所生成数据可靠性的重要性。未能确保这些数据的可靠性可能会给美国数百万人的健康管理带来潜在风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验